Widely used:Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹793 Cr
P/E Ratio
97.04
P/B Ratio
13.81
Industry P/E
35.02
Debt to Equity
0.05
ROE
44.7 %
ROCE
44.24 %
Div. Yield
0.14 %
Book Value
1.31
EPS
1.87
CFO
₹9.23 Cr
EBITDA
₹36.30 Cr
Net Profit
₹25.66 Cr
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Shukra Pharma
| 32.87 | -24.66 | -17.71 | 105.68 | 269.19 | 149.18 | 41.49 |
|
BSE Healthcare
| -4.95 | 1.92 | -0.50 | 24.13 | 20.27 | 23.08 | 9.93 |
|
BSE Small Cap
| -10.08 | 4.17 | -3.87 | 5.97 | 18.98 | 35.50 | 15.85 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Shukra Pharma
| 349.69 | 349.91 | 58.55 | 94.61 | -20.12 | 15.12 | -11.01 |
|
BSE Small Cap
| 29.04 | 47.52 | -1.80 | 62.77 | 32.11 | -6.85 | -23.41 |
|
BSE Healthcare
| 43.09 | 36.97 | -12.10 | 20.87 | 61.45 | -3.55 | -5.89 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | P/E Ratio | ROE |
|---|---|---|---|---|
| 753.90 | 6,836.12 | 27.42 | 13.8 | |
| 2,202.50 | 9,009.27 | 74.22 | 12.96 | |
| 416.75 | 5,136.09 | 68.88 | 6.24 | |
| 910.95 | 5,226.93 | 41.03 | 14.76 |
No Review & Analysis are available.
Manufacture of allopathic pharmaceutical preparations
Incorporated
1993
Chairman
--
Managing Director
Dakshesh Rameshchandra Shah
Headquarters
Ahmedabad, Gujarat
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The total asset value of Shukra Pharmaceuticals Ltd stood at ₹ 81 Cr as on 31-Dec-24
The share price of Shukra Pharmaceuticals Ltd is ₹18.12 (BSE) as of 24-Apr-2025 IST. Shukra Pharmaceuticals Ltd has given a return of 269.19% in the last 3 years.
Shukra Pharmaceuticals Ltd has a market capitalisation of ₹ 793 Cr as on 24-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Shukra Pharmaceuticals Ltd is 13.81 times as on 24-Apr-2025, a 268% premium to its peers’ median range of 3.75 times.
The P/E ratio of Shukra Pharmaceuticals Ltd is 97.04 times as on 24-Apr-2025, a 177% premium to its peers’ median range of 35.02 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Shukra Pharmaceuticals Ltd and enter the required number of quantities and click on buy to purchase the shares of Shukra Pharmaceuticals Ltd.
Manufacture of allopathic pharmaceutical preparations
The prominent promoters of Shukra Pharmaceuticals Ltd. are
| Name of promoters | Holding percentage |
|---|---|
|
ANAR PROJECT PRIVATE LIMITED |
18.78%
|
|
PARSHVA TEXCHEM INDIA PRIVATE LTD. |
17.17%
|
|
NAVKAR SURGICAL GUJARAT |
11.78%
|
The chairman of the company is , and the managing director is Dakshesh Rameshchandra Shah.
There is no promoter pledging in Shukra Pharmaceuticals Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
9,512
|
|
|
6,653
|
|
|
5,320
|
|
|
5,217
|
| Shukra Pharmaceuticals Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
14.61
|
|
Operating margin(%)
|
24.07
|
|
Net Margin(%)
|
23.82
|
|
Dividend yield(%)
|
0.14
|
Yes, TTM profit after tax of Shukra Pharmaceuticals Ltd was ₹8 Cr.
₹-0.74
(
